Impact of renal function on clopidogrel-induced antiplatelet effects in coronary artery disease patients without diabetes mellitus

Journal of Thrombosis and Thrombolysis

Volumn 36, Issue 1, 2013, Pages 14-17

  Tello Montoliu, Antonio ^a   Ferreiro, Jose Luis ^a   Kodali, Murali K ^a   Ueno, Masafumi ^a   Tomasello, Salvatore D ^a   Rollini, Fabiana ^a   Capodanno, Davide ^a   Darlington, Andrew ^a   Patel, Ronakkumar ^a   Desai, Bhaloo ^a   Guzman, Luis A ^a   Bass, Theodore A ^a   Angiolillo, Dominick J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Chronic kidney disease; Clopidogrel; Platelet function

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; PROSTAGLANDIN E1; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; LOADING DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PLATELET REACTIVITY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; TICLOPIDINE;

EID: 84879210083     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-012-0828-1     Document Type: Article

References (10)

1. Ferreiro JL, Angiolillo DJ (2011) Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation 123:798-813
2. Capodanno D, Angiolillo DJ (2012) Antithrombotic therapy in patients with chronic kidney disease. Circulation 125:2649-2661
3. Angiolillo DJ, Bernardo E, Capodanno D et al (2010) Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. J Am Coll Cardiol 55:1139-1146
4. Park SH, Kim W, Park CS, Kang WY, Hwang SH, Kim W (2009) A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure. Am J Cardiol 104:1292-1295
5. Motovska Z, Odvodyova D, Fischerova M et al (2012) Renal function assessed using cystatin C and antiplatelet efficacy of clopidogrel assessed using the vasodilator-stimulated phosphoprotein index in patients having percutaneous coronary intervention. Am J Cardiol 109:620-623
6. Morel O, El Ghannudi S, Jesel L et al (2011) Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel. J Am Coll Cardiol 57:399-408
7. Cockcroft D (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41
8. American Diabetes Association (2012) Diagnosis and classification of diabetes mellitus. Diabetes Care 35:S64-S71
9. Angiolillo DJ, Shoemaker SB, Desai B et al (2007) Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the optimizing antiplatelet therapy in diabetes mellitus (OPTIMUS) study. Circulation 115:708-716
10. Bonello L, Tantry US, Marcucci R et al (2010) Working group on high on-treatment platelet reactivity. Consensus and future directions on the definition of high ontreatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 56:919-933